Vivos Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held on July 28, 2021. The filing date is July 29, 2021. Vivos Therapeutics, Inc. is an emerging growth company incorporated in Delaware, with its common stock (VVOS) trading on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Approximately 16,400,000 shares were present or represented by proxy at the meeting, out of 22,812,119 shares entitled to vote. Stockholders approved three key proposals:
- Election of Directors: Seven nominees were elected to one-year terms: Dr. G. Dave Singh, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, Dr. Matthew Thompson, and R. Kirk Huntsman. All received significant support, with "For" votes ranging from approximately 10.15 million to 11.21 million shares.
- Stock Plan Amendment: Stockholders approved an amendment to the Amended and Restated 2019 Stock Option and Issuance Plan, increasing the authorized share pool from 1,166,667 to 2,366,667 shares. The proposal passed with 9,108,810 votes "For" and 2,608,040 votes "Against."
- Auditor Ratification: The appointment of Plante & Moran, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified with 15,745,088 votes "For."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the annual meeting results.
Investor Verification Checklist
- Verify the impact of the increased stock option pool (2,366,667 shares) on potential future dilution.
- Confirm the composition of the newly elected Board of Directors and their tenure terms.
- Review the full proxy statement for detailed biographies of the elected directors and the rationale behind the stock plan amendment.
- Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2021, as this 8-K does not contain financial data.